ReviewClinical and molecular hepatology2023
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
Review in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Natural Autoantibodies Negatively Correlate with Hepatocellular Carcinoma Incidence in Cirrhosis.Cancer research communications · 2026Article
- Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control.Global health research and policy · 2025Article
- Association Between Depression and Hepatic Steatosis According to Obese Status: The Korean National Health and Nutrition Examination Survey 2010-2019.Medicina (Kaunas, Lithuania) · 2025Article
- High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2025Article
- Review
- Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.Clinical and molecular hepatology · 2025Review
- A CART-based prognostic model for risk stratification of postoperative early recurrence in hepatocellular carcinoma with microvascular invasion.Frontiers in oncology · 2025Article
- NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.International journal of molecular sciences · 2025Review
- Association Between Dietary Inflammatory Index and NAFLD: A Cross-Sectional Study of the National Health and Nutrition Examination Survey.Mediators of inflammation · 2025Article
- Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes.JHEP reports : innovation in hepatology · 2024Article
- Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets.Journal of clinical medicine · 2024Article
- Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma.Clinical and molecular hepatology · 2024Article
- MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options.Current issues in molecular biology · 2024Review
- Article
- A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma.Hepatology international · 2024Article
- A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.Frontiers in medicine · 2024Review
- Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis.Diagnostics (Basel, Switzerland) · 2023Review
- The latest global burden of liver cancer: A past and present threat.Clinical and molecular hepatology · 2023Article
- Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma.Clinical and molecular hepatology · 2023Article
- Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease - who and how?Clinical and molecular hepatology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non-cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.